Aurobindo Pharma Ltd (AUROPHARMA) — Corporate Action | 1 October 2026

1 October 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Apitoria acquires 100% of A1 Labs, former promoter retains 20% stake

🔄 What Changed

A1 Labs ceases to be wholly-owned subsidiary; 20% stake now held by former promoter

🔮 What's Next

Apitoria may acquire the 20% stake in future as per definitive agreements

💡 Investor Takeaway

Routine procedural filing with no direct impact on shareholders.

Aurobindo Pharma announced that its subsidiary Apitoria acquired 100% of A1 Biochem Labs, but Dr. Rajendra Gadikota, former promoter, now holds a 20% stake via 89,94,500 equity shares and 2,41,05,500 convertible debentures, making A1 Labs a step-down subsidiary. The transaction was completed on September 30, 2026, with INR 9.18 Cr received for equity shares and INR 24.62 Cr for debentures, and is classified as a related party transaction at arm’s length.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹95,886.73 CrP/E: 26.0ROE: 9.8%ROCE: 12.8%Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How will the 20% stake affect A1 Labs' valuation?""What are the terms for Apitoria's future acquisition of the stake?""How does this impact Aurobindo's overall subsidiary structure?"

Ask AI Free →

📊 More AUROPHARMA filings

🔴 Announcement — 30 September 2026Aurobindo Pharma's subsidiary Acrotech Biopharma launched ADQUEY™ (difamilast 1% ointment), a non-st...
🔴 Announcement — 29 September 2026Aurobindo Pharma disclosed a GST appellate order confirming reversal of Rs. 2.56 crore excess input ...
Announcement — 24 September 2026Aurobindo Pharma announced that its trading window will close on October 1, 2026, for all designated...
🔴 Announcement — 21 September 2026Aurobindo Pharma announced its participation in a JP Morgan Healthcare Trip investor meeting in Hyde...
🔴 Announcement — 15 September 2026Aurobindo Pharma announced the completion of a US FDA inspection at its Apitoria Pharma subsidiary's...

See all AUROPHARMA filings →

🔥 Also filed on 1 October 2026

GCSLGretex Corporate Services LtdOffer Document PVPPVP Ventures LtdAnnouncement 501261Lords Mark Industries LimitedInsider Trading AVALONAvalon Technologies LtdInsider Trading HINDZINCHindustan Zinc LtdInsider Trading 542446Jonjua Overseas LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.